Fosfomycin for the Treatment of Prostate Infection

Hideharu Hagiya; Megumi Ninagawa; Kou Hasegawa; Tomohiro Terasaka; Kosuke Kimura; Koichi Waseda; Yoshihisa Hanayama; Toshiaki Sendo; Fumio Otsuka

doi:10.2169/internalmedicine.53.3098

CASE REPORTS

Fosfomycin for the Treatment of Prostate Infection

Hideharu Hagiya, Megumi Ninagawa, Kou Hasegawa, Tomohiro Terasaka, Kosuke Kimura, Koichi Waseda, Yoshihisa Hanayama, Toshiaki Sendo, Fumio Otsuka

Author information

Hideharu Hagiya
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Megumi Ninagawa
Department of Pharmacy, Okayama University Hospital, Japan
Kou Hasegawa
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Tomohiro Terasaka
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Kosuke Kimura
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Koichi Waseda
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Yoshihisa Hanayama
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Toshiaki Sendo
Department of Pharmacy, Okayama University Hospital, Japan
Fumio Otsuka
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

Keywords: chronic bacterial prostatitis, fluoroquinolone, fosfomycin, prostate abscess, revival of antibiotics

JOURNAL OPEN ACCESS

2014 Volume 53 Issue 22 Pages 2643-2646

DOI https://doi.org/10.2169/internalmedicine.53.3098

Details

Abstract

A 69-year-old man with diabetes mellitus was diagnosed with a prostate abscess. Although the pathogen was fluoroquinolone-resistant Escherichia coli and the oral administration of trimethoprim-sulfamethoxazole was initiated, the infection recurred after three months. The antibiotic therapy was subsequently changed to intravenous fosfomycin, and the patient's condition promptly improved. Four weeks of fosfomycin therapy was successfully continued without any adverse events. In the era of antibiotic resistance, revival of forgotten drugs is an important issue for clinicians. Fosfomycin can be applied as an alternative option for prostate infections, considering the remaining susceptibility of multidrug-resistant pathogens to fosfomycin and the good pharmacokinetics of this drug in prostatic tissue.

Corresponding author

Register with J-STAGE for free!